The Trump administration’s two signature efforts to address drug prices and out of pocket costs are now pending review at the White House Office of Management and Budget.
The final rule eliminating the safe harbor for drug rebates in Medicare Part D and Medicaid managed care was received by OMB on 10 June. Prior to that, the Centers for Medicare and Medicaid Services formally notified Medicare Part D insurers that there would be no changes to the rebate safe harbor before 2020 bids to provide drug benefits were due 3 June